FDA Clearance Tracker · P150004-S085
Proclaim Dorsal Root Ganglion (DRG) Neurostimulator System
Last checked: Nov 20, 2026Latest source record: Jan 13, 2026 (this decision)Source: openFDAMethods & limitations
Decided
Jan 13, 2026
Approved
Time to decision
223 days
Received Jun 4, 2025. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track
Device class
Class III
The decision
- FDA number
- P150004-S085
- Device name
- Proclaim Dorsal Root Ganglion (DRG) Neurostimulator System
- Applicant
- ABBOTT MEDICAL
- Applicant location
- Plano, TX
- Received
- Jun 4, 2025
- Decided
- Jan 13, 2026
- Decision
- Approved
- Supplement type
- Normal 180 Day Track
- Reason for supplement
- Labeling Change - Indications/instructions/shelf life/tradename
- Original approval
- P150004
Device type
- Device class
- Class III
FDA's approval statement
As written in FDA's record.
Approval for expanded MR Conditional labeling to include prone positioning for the Proclaim DRG System.
Source documents
Other decisions for ABBOTT MEDICAL
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
P260019 · Decided Oct 27, 2026 · 180 days after receipt
Device type: Para-device leak occluder (SJT) · Cardiology
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.